BEAM•benzinga•
Beam Therapeutics Q4 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate, Ended Fourth Quarter 2024 with $850.7M in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga